Journal article
Differential Impact of Delayed Graft Function in Deceased Donor Renal Transplant Recipients With and Without Donor-specific HLA-antibodies.
-
Haller J
Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
-
Wehmeier C
Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
-
Hönger G
Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
-
Hirt-Minkowski P
Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
-
Gürke L
Vascular and Transplantation Surgery, University Hospital Basel, Basel, Switzerland.
-
Wolff T
Vascular and Transplantation Surgery, University Hospital Basel, Basel, Switzerland.
-
Steiger J
Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
-
Amico P
Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
-
Dickenmann M
Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
-
Schaub S
Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
Show more…
English
BACKGROUND
Delayed graft function (DGF) and pretransplant donor-specific HLA-antibodies (DSA) are both regarded as risk factors for rejection and lower graft survival. However, the combined impact of DGF and DSA has not been studied in detail.
METHODS
We investigated 375 deceased donor kidney transplantations, which had DSA assignment by single-antigen bead technology and which had surveillance biopsies at 3 of 6 months. Median follow-up time was 6.1 years.
RESULTS
DGF occurred in 137 of 375 patients (37%), and DSA were present in 85 of 375 patients (23%). The incidence of DGF was similar in DSA-positive (DSApos)-patients and DSA-negative (DSAneg)-patients (40% versus 36%; P = 0.45). In DSAneg-patients, 5-year graft survival was not different with/without DGF (81% versus 83%; P = 0.48). By contrast, in DSApos-patients, 5-year graft survival was significantly lower with DGF (64% versus 79%; P = 0.01). Moreover, DSApos-patients with DGF had a higher 1-year incidence of subclinical rejection, which were mostly antibody-mediated or mixed rejection phenotypes. Graft loss due to rejection was significantly more frequent in DSApos-patients with DGF (5/34; 15%) compared to DSApos-patients without DGF (2/51; 4%), and DSAneg-patients with/without DGF (3/103; 3% and 4/187; 2%, respectively) (P = 0.005). In a multivariate Cox model, DSA with DGF was an independent predictor for graft (hazard ratio = 2.84 [95% confidence interval, 1.54-5.06]; P = 0.001) and death-censored graft loss (hazard ratio = 4.65 [95% confidence interval, 1.83-11.51]; P = 0.002).
CONCLUSIONS
DGF has a much more detrimental impact in DSApos-patients than in DSAneg-patients, which is likely related to a higher incidence of antibody-mediated rejection. If possible, the combined risks of DGF and DSA should be avoided.
-
Language
-
-
Open access status
-
closed
-
Identifiers
-
-
Persistent URL
-
https://sonar.ch/global/documents/73398
Statistics
Document views: 7
File downloads: